ライフサイエンスコーパス: vascular endothelial

1 rovide a framework and mechanistic model for vascular endothelial adaptation to hypoxia in lowlanders

2 ll documented that metabolic syndrome alters vascular endothelial and smooth muscle cell functions in

3 ociated with changes in permeability such as vascular endothelial cadherin (VE-Cadherin) and neuropil

4 tein kinase 3 (RIPK3) and destabilization of vascular endothelial cadherin (VE-cadherin) at EC juncti

5 ction and the proteolytic disorganization of vascular endothelial cadherin (VE-cadherin) in HUVECs in

6 the inhibition of phosphorylation of Src and vascular endothelial cadherin (VE-cadherin), which incre

7 ated Src and higher levels of phosphorylated vascular endothelial cadherin at adherens junctions comp

8 Mechanistically, PHD2 knockdown induces vascular endothelial cadherin in mouse lung microvascula

9 ly expression of endothelial markers such as vascular endothelial cadherin(VECAD) and occludin but lo

10 diabetic retinas by causing dissociation of vascular endothelial-cadherin from beta-catenin.

11 atelet endothelial cell adhesion molecule 1, vascular endothelial-cadherin, and CD34) and an endothel

12 Vascular endothelial cell (EC) dysfunction plays a key r

13 y depend on circulating tumor cell (CTC) and vascular endothelial cell (EC) interactions by incomplet

14 oteins in beta-catenin signaling, we studied vascular endothelial cell (EC)-specific knockout of Dlg1

15 of nonhealers, were mainly expressed by the vascular endothelial cell cluster almost exclusively in

16 retina, and electron microscopy demonstrated vascular endothelial cell irregularity with narrowing of

17 isms that drive angiogenesis and organotypic vascular endothelial cell specialization are poorly unde

18 C cells and in soluble Pfn1's involvement in vascular endothelial cell tumor cell cross-talk.

19 Blood vascular endothelial cells (BECs) control the immune res

20 Vascular endothelial cells (ECs) derived from the centra

21 the activation of the gene transcriptions in vascular endothelial cells (ECs) plays an essential role

22 se that is driven, in part, by activation of vascular endothelial cells (ECs).

23 of early postnatal inactivation of Kif11 in vascular endothelial cells (ECs).

24 n C5a receptor 1 [C5aR1]) on human umbilical vascular endothelial cells (HUVECs) and examined how C3a

25 Here, we generated induced vascular endothelial cells (iVECs) and smooth muscle cel

26 straints of bioprinted scaffolds-the 'reset' vascular endothelial cells (R-VECs) self-assemble into s

27 m of trigeminal ganglion sensory neurons and vascular endothelial cells (VEC) and found that neurons

28 tionally deleted a floxed allele of Podxl in vascular endothelial cells (vECs) using Tie2Cre mice (Po

29 ular endothelial growth factor receptor 2 in vascular endothelial cells abolished injury-induced HA a

30 In both retina and brain, vascular endothelial cells activate a previously dormant

31 Using primary human retinal vascular endothelial cells and an established human endo

32 consisting of patient-derived tumour cells, vascular endothelial cells and decellularized extracellu

33 y expressed unconventional myosin in retinal vascular endothelial cells and expression levels increas

34 vents that govern hemogenic specification of vascular endothelial cells and the generation of multili

35 unb-malate MS mitigated the proliferation of vascular endothelial cells and the recruitment of mural

36 monocytogenes infection among primary human vascular endothelial cells can be attributed entirely to

37 r cells, tumor-infiltrating lymphocytes, and vascular endothelial cells compete for oxygen and nutrie

38 indicate that Adora2a-mediated signaling in vascular endothelial cells disrupts the BBB in dietary o

39 efining the molecular signatures of coronary vascular endothelial cells during these complex processe

40 els were elevated in human keratinocytes and vascular endothelial cells following IL-26 stimulation.

41 requirement of mitochondrial respiration in vascular endothelial cells for neoangiogenesis during de

42 al up-regulation of Pfn1 in tumor-associated vascular endothelial cells in the clinical specimens of

43 mab-induced interactions between T cells and vascular endothelial cells in vitro and in patients.

44 momab-induced T-cell rolling and adhesion to vascular endothelial cells in vitro, and (v) the ability

45 lating lymphocyte function via activation of vascular endothelial cells is unknown.

46 gs are nitrated, (6) cytoplasmic vesicles in vascular endothelial cells known to stain for NADPH diap

47 naling via the S1P receptor 1 (S1PR1) in the vascular endothelial cells of lung and kidney.

48 Meanwhile, mesenteric arteries and lung vascular endothelial cells of tamoxifen-inducible endoth

49 ion induced ectopic podoplanin expression in vascular endothelial cells or macrophages, which may als

50 ptional and spatial gradients-emanating from vascular endothelial cells outwards-in fibroblasts.

51 Rickettsia conorii infects vascular endothelial cells producing disseminated plasma

52 od-borne transport of miR-210 into pulmonary vascular endothelial cells promotes PH, offering fundame

53 livery of extracellular miR-210 to pulmonary vascular endothelial cells promotes PH.

54 Vascular endothelial cells respond to blood flow-induced

55 Vascular endothelial cells respond to proangiogenic cues

56 ss requires the specification of a subset of vascular endothelial cells to become blood-forming, or h

57 ric acid induced the phenotype transition of vascular endothelial cells via induction of oxidative st

58 Incubation of vascular endothelial cells with saturated fatty acid (SF

59 ure of islets on 3D-ECM promoted recovery of vascular endothelial cells within the islets and restore

60 s demonstrated, involving mainly stromal and vascular endothelial cells within the tissue.

61 nal and non-neuronal (astrocytes, microglia, vascular endothelial cells) cells of cortical (medial pr

62 ocytes, macrophages, CD4+ T cells, and micro-vascular endothelial cells).

63 ch is expressed on the surface of angiogenic vascular endothelial cells, but is absent in quiescent e

64 timulation of non-excitable cells, including vascular endothelial cells, calcium (Ca(2+)) shuttling b

65 In vascular endothelial cells, cysteine metabolism by the c

66 on of CD31, which indicates presence of more vascular endothelial cells, was associated with signific

67 he crosstalk between EphA4-Tie2 signaling in vascular endothelial cells, which is mediated through p-

68 Vascular endothelial cells, which line the lumen of bloo

69 istent increased vascular resistance damages vascular endothelial cells-a marker of which is increase

70 SS transcripts inhibits monocyte adhesion to vascular endothelial cells.

71 preferential T-cell homing via modulation of vascular endothelial cells.

72 ytes and lymphatic endothelial cells but not vascular endothelial cells.

73 ycan-bound chemokines on the luminal side of vascular endothelial cells.

74 yx is a layer coating the luminal surface of vascular endothelial cells.

75 nical models through localized insult to the vascular endothelial cells.

76 id droplets by increasing autophagic flux in vascular endothelial cells.

77 models caused increased arterial stiffness, vascular endothelial changes, increased angiogenesis, ca

78 erinflammatory milieu in the circulation and vascular endothelial damage markers within patients with

79 r cardiovascular diseases, driven largely by vascular endothelial dysfunction (impaired endothelium-d

80 treatment may have a role in preventing the vascular endothelial dysfunction associated with As expo

81 ntroversy remains about how diet affects the vascular endothelial dysfunction associated with disorde

82 ogenitors, thus restricting these cells to a vascular endothelial fate.

83 Receptor signaling is central to vascular endothelial function and is dysregulated in vas

84 Studies on vaping and vascular endothelial function and the whole-body MRI dep

85 inflammatory response, and disruption of the vascular endothelial function in patients with LI.

86 on on presentation; (3) no intravitreal anti-vascular endothelial growth factor (anti-VEGF) injection

87 er surgery, laser photocoagulation, and anti-vascular endothelial growth factor (anti-VEGF) treatment

88 nd exudative AMD eyes and the impact of anti-vascular endothelial growth factor (anti-VEGF) treatment

89 Delivery of siRNA against vascular endothelial growth factor (siVEGF) at extremely

90 engineered to bind a key signaling protein, vascular endothelial growth factor (VEGF(165)), function

91 Super responders had increased baseline vascular endothelial growth factor (VEGF) (880.0 pg/mL v

92 activity following 3 loading doses of anti- vascular endothelial growth factor (VEGF) agents, and th

93 iates angiogenesis through the expression of vascular endothelial growth factor (VEGF) and can be ind

94 MP0250 specifically inhibits both vascular endothelial growth factor (VEGF) and hepatocyte

95 Vascular endothelial growth factor (VEGF) and placental

96 Vascular endothelial growth factor (VEGF) and semaphorin

97 tion, triggered by the angiogenesis inducers Vascular Endothelial Growth Factor (VEGF) and Sphingosin

98 poxia inducible factor-1 alpha (HIF-1alpha), vascular endothelial growth factor (VEGF) and tumor necr

99 Here, we uncovered vascular endothelial growth factor (VEGF) as a novel ind

100 Vascular endothelial growth factor (VEGF) contributes to

101 submucosa (SIS) immobilized with heparin and vascular endothelial growth factor (VEGF) could be impla

102 and treatment frequency and switches in anti-vascular endothelial growth factor (VEGF) drug.

103 sion, but not that of TWIST1 alone, enhanced vascular endothelial growth factor (VEGF) expression via

104 roduction of anti-angiogenic drugs targeting vascular endothelial growth factor (VEGF) has transforme

105 ssion of other LPS-induced factors including vascular endothelial growth factor (VEGF) in both cell t

106 ith a VE-cadherin reporter demonstrated that vascular endothelial growth factor (VEGF) induces VE-cad

107 ibitor Ro5-3335, aflibercept-an FDA-approved vascular endothelial growth factor (VEGF) inhibitor, or

108 e evidence supports the safety of suspending vascular endothelial growth factor (VEGF) inhibitors for

109 ence and nonpersistence to intravitreal anti-vascular endothelial growth factor (VEGF) injection ther

110 Intravitreal anti-vascular endothelial growth factor (VEGF) injections are

111 tively followed on a monthly basis with anti-vascular endothelial growth factor (VEGF) injections whe

112 re dictates frequent intravitreal (IVT) anti-vascular endothelial growth factor (VEGF) injections, wh

113 Vascular endothelial growth factor (VEGF) is a key regul

114 acquired demyelinating neuropathy with serum vascular endothelial growth factor (VEGF) more accuratel

115 time (to our knowledge) the critical role of vascular endothelial growth factor (VEGF) on thymic morp

116 Intravitreal anti-vascular endothelial growth factor (VEGF) pharmacotherap

117 Intravitreal anti-vascular endothelial growth factor (VEGF) pharmacotherap

118 s after bleomycin treatment was dependent on vascular endothelial growth factor (Vegf) receptor 3 sig

119 BafA interacts with vascular endothelial growth factor (VEGF) receptor-2 and

120 nsepithelial resistance, predicted polarized vascular endothelial growth factor (VEGF) secretion, and

121 actor (EGF), hepatocyte growth factor (HGF), vascular endothelial growth factor (VEGF) showed time-de

122 ine kinase (RTK) inhibitor sunitinib, target vascular endothelial growth factor (VEGF) signaling in c

123 ated by the skeletogenic cells controlled by vascular endothelial growth factor (VEGF) signaling.

124 nthase 2 are uniquely sensitive to increased vascular endothelial growth factor (VEGF) stimulation du

125 rfin photodynamic therapy (PDT) and (2) anti-vascular endothelial growth factor (VEGF) therapies, whi

126 Anti-vascular endothelial growth factor (VEGF) therapy has be

127 This study assessed anti-vascular endothelial growth factor (VEGF) therapy intens

128 Approximately 50% of patients receiving anti-vascular endothelial growth factor (VEGF) therapy show s

129 CNF1 induced bladder cancer cells to secrete vascular endothelial growth factor (VEGF) through activa

130 ssed the effects of continuing the same anti-vascular endothelial growth factor (VEGF) treatment amon

131 acular degeneration (nAMD) who received anti-vascular endothelial growth factor (VEGF) treatment for

132 Anti-vascular endothelial growth factor (VEGF) treatment of n

133 l-world baseline visual acuity (VA) and anti-vascular endothelial growth factor (VEGF) treatment patt

134 Predictors of anti-vascular endothelial growth factor (VEGF) use and number

135 erivatives (sGAG) influence the interplay of vascular endothelial growth factor (VEGF)(165) and its h

136 f proliferating cell nuclear antigen (PCNA), vascular endothelial growth factor (VEGF), and osteopont

137 d PI3K/mammalian target of rapamycin (mTOR), vascular endothelial growth factor (VEGF), and WNT signa

138 SCs displayed robust and stable secretion of vascular endothelial growth factor (VEGF), brain-derived

139 P), epidermal growth factor receptor (EGFR), Vascular endothelial growth factor (VEGF), etc.

140 Vascular endothelial growth factor (VEGF), Interleukin 6

141 the promoters of HIF target genes, including vascular endothelial growth factor (VEGF), where it enha

142 Vascularisation is dependent upon vascular endothelial growth factor (VEGF), which drives

143 Clinical trials aimed at inducing vascular endothelial growth factor (VEGF)-A levels, a po

144 bility to release the proangiogenic mediator vascular endothelial growth factor (VEGF)-A.

145 OPT-302 is a novel inhibitor of vascular endothelial growth factor (VEGF)-C and VEGF-D.

146 Herein, we identified that vascular endothelial growth factor (VEGF)-C, a potent ly

147 h doxycycline-inducible expression of murine vascular endothelial growth factor (VEGF)-D under a tigh

148 vascular roles of GIPCs beyond those of the Vascular Endothelial Growth Factor (VEGF)-dependent, pro

149 -phosphate receptors (S1PRs), which restrain vascular endothelial growth factor (VEGF)-induced angiog

150 Furthermore, vascular endothelial growth factor (VEGF)-induced EC mig

151 only treated with intravitreal injections of vascular endothelial growth factor (VEGF)-neutralizing a

152 migrate thymus-derived regulatory T cells to vascular endothelial growth factor (VEGF)-producing tumo

153 s accompanied by complete absence of hepatic vascular endothelial growth factor (VEGF)-stromal cell-d

154 tinopathy, is driven by chronic elevation of vascular endothelial growth factor (VEGF).

155 rs, bone morphogenetic protein 2 (BMP-2) and vascular endothelial growth factor (VEGF).

156 eceptor tyrosine kinase agonists insulin and Vascular Endothelial Growth Factor (VEGF).

157 ypoxia-inducible factor-1alpha (HIF-1alpha), vascular endothelial growth factor (VEGF-A), and clinica

158 e expression of ISL2, the angiogenic markers vascular endothelial growth factor (VEGFA) and CD31 and

159 Acting as a partial agonist of vascular endothelial growth factor 2 (VEGFR2), soluble d

160 nt possible initial treatments for DME (anti-vascular endothelial growth factor [VEGF], focal laser t

161 ines known to promote vascular leak, such as vascular endothelial growth factor A (VEGF).

162 Vascular endothelial growth factor A (VEGF-A) and its bi

163 adermal injections of modified mRNA encoding vascular endothelial growth factor A (VEGF-A) or buffere

164 porter 1 (GLUT-1), erythropoietin (EPO), and vascular endothelial growth factor A (VEGF-A) were analy

165 sion of two critical pro-angiogenic factors, vascular endothelial growth factor A (VEGF-A), and VEGF-

166 ntibodies targeting 2 proangiogenic factors, vascular endothelial growth factor A (VEGFA) and angiopo

167 Blockade of vascular endothelial growth factor A (VEGFA) and angiopo

168 Whereas therapies targeting vascular endothelial growth factor A (VEGFA) can suppres

169 cting c-Myc and transcriptionally repressing vascular endothelial growth factor A (VEGFA) expression.

170 tralization of proangiogenic factors such as vascular endothelial growth factor A (VEGFA) has had lim

171 Vascular endothelial growth factor A (VEGFA) stimulates

172 n segments, producing a correlative level of vascular endothelial growth factor A (VEGFA) to define a

173 RRalpha depletion increased basal as well as vascular endothelial growth factor A (VEGFA)- and ANG1/2

174 scein isothiocyanate-dextran), and prevented vascular endothelial growth factor A (VEGFA)-induced bar

175 the autophagic degradation of intracellular vascular endothelial growth factor A (VEGFA).

176 Inhibition of vascular endothelial growth factor A (VEGFA)/vascular en

177 (Ki67, vascular endothelial growth factor-A vascular endothelial growth factor A [VEGF-A], and termi

178 Finally, we demonstrate the efficacy of anti-vascular endothelial growth factor A blockade for prohib

179 rcted myocardium, thereby diminishing Vegfa (vascular endothelial growth factor A) interaction with H

180 ith reduction of its transcriptional target, vascular endothelial growth factor A, in clodronate-trea

181 mice and neuraminidase-treated IgG inhibited vascular endothelial growth factor activation of endothe

182 Anti-vascular endothelial growth factor acts faster than lase

183 luded observation (n = 1), intravitreal anti-vascular endothelial growth factor agents (n = 4), vitre

184 the potential differential efficacy of anti-vascular endothelial growth factor agents in the treatme

185 Treatment with anti-vascular endothelial growth factor agents.

186 eriodontal bone level and the expressions of vascular endothelial growth factor and core-binding fact

187 Finally, TO reduced gene expression of vascular endothelial growth factor and surfactant protei

188 findings suggest that a rise in intraocular vascular endothelial growth factor as a consequence of m

189 sociated with a significant decrease in free vascular endothelial growth factor but was associated wi

190 Adeno-associated virus 8-vascular endothelial growth factor C (AAV8-VEGF-C) was i

191 However, ectopic expression of vascular endothelial growth factor C (VEGF-C) promotes e

192 demonstrate that the lymphangiogenic factors vascular endothelial growth factor C (VEGFC) and VEGFD a

193 In the adult brain, vascular endothelial growth factor D (VEGFD) is required

194 We found a link between hypoxia-dependent vascular endothelial growth factor expression in tumor d

195 their inflammatory program by CD1d-dependent vascular endothelial growth factor expression.

196 lysis revealed elevated levels of angiogenic vascular endothelial growth factor in the clopidogrel gr

197 s highlight the need for therapy beyond anti-vascular endothelial growth factor inhibition to address

198 nhibitor vorinostat combined with either the vascular endothelial growth factor inhibitor pazopanib (

199 amenable to treatment with intravitreal anti-vascular endothelial growth factor injection was observe

200 . 299 +/- 103mum; P = 0.527), number of anti-vascular endothelial growth factor injections (6.5 +/- 2

201 They were given retreatment anti-vascular endothelial growth factor injections according

202 Population: Eyes receiving intravitreal anti-vascular endothelial growth factor injections from July

203 ologists performing either intravitreal anti-vascular endothelial growth factor injections or posteri

204 al fluid, including some combination of anti-vascular endothelial growth factor injections, photodyna

205 months who had received 2 or more prior anti-vascular endothelial growth factor intravitreal injectio

206 spectively; similar to results obtained with vascular endothelial growth factor neutralization.

207 cancer is based mainly on inhibition of the vascular endothelial growth factor pathway.

208 ologous renal tumour cell vaccine and of the vascular endothelial growth factor receptor (VEGFR) tyro

209 e progression in metastatic RCC treated with vascular endothelial growth factor receptor (VEGFR) tyro

210 a highly coordinately process controlled by vascular endothelial growth factor receptor (VEGFR)-Notc

211 ts from computational methods predicted that Vascular Endothelial Growth Factor Receptor 1 (VEGFR1) c

212 phase, triggering apoptosis, and inhibiting vascular endothelial growth factor receptor 2 (VEGFR-2)

213 dent signaling event, m-SCF/c-Kit and VEGF-A/vascular endothelial growth factor receptor 2 (VEGFR-2),

214 Vascular endothelial growth factor receptor 2 (VEGFR2) c

215 isms regulate the crosstalk between IL-6 and vascular endothelial growth factor receptor 2 (VEGFR2) s

216 vascular endothelial growth factor A (VEGFA)/vascular endothelial growth factor receptor 2 (VEGFR2) s

217 (1) macrophage recruitment after injury; (2) vascular endothelial growth factor receptor 2 (VegfR2) s

218 his complex a slightly reduced expression of vascular endothelial growth factor receptor 2 (VEGFR2) w

219 ication of endothelial glycoproteins such as vascular endothelial growth factor receptor 2 (VEGFR2) w

220 endently validate KDR, which encodes for the Vascular Endothelial Growth Factor Receptor 2 (VEGFR2),

221 eceptor (EGFR)-EPH receptor A2 (EPHA2), EGFR-vascular endothelial growth factor receptor 2 (VEGFR2),

222 Glycocalyx regulation of vascular endothelial growth factor receptor 2 activity.

223 Ramucirumab-an IgG1 vascular endothelial growth factor receptor 2 antagonist

224 VEGFR2lox/PGFD mice, conditional deletion of vascular endothelial growth factor receptor 2 in vascula

225 ulation and subsequent activation of VEGFR2 (vascular endothelial growth factor receptor 2) and decre

226 rowth factor 2), and their receptors VEGFR2 (vascular endothelial growth factor receptor 2) and FGFR1

227 uronan receptor 1), neuropilin-1 and VEGFR2 (vascular endothelial growth factor receptor 2), whereas

228 focusing on VEGF(165)b's role in inhibiting vascular endothelial growth factor receptor 2-dependent

229 pression of EC markers (VE-cadherin, VEGFR2 [vascular endothelial growth factor receptor 2], or VWF [

230 point inhibition plus agents that target the vascular endothelial growth factor receptor and a shift

231 MRI may assist in identifying responders to vascular endothelial growth factor receptor tyrosine kin

232 th a mode-of-action complementary to VEGF-R (vascular endothelial growth factor receptor)-targeted th

233 uggested that GREM1 can bind to and activate vascular endothelial growth factor receptor-2 (VEGFR2) i

234 ther than vascular endothelial growth factor-vascular endothelial growth factor receptor-mediated ang

235 ctic treatment and if eyes treated with anti-vascular endothelial growth factor therapy are at risk o

236 ter vision improvements when consistent anti-vascular endothelial growth factor therapy is maintained

237 Anti-vascular endothelial growth factor therapy results in be

238 betic macular edema requiring bilateral anti-vascular endothelial growth factor therapy were included

239 emi) central RVO who might benefit from anti-vascular endothelial growth factor treatment were eligib

240 clinically relevant human alpha-thrombin and vascular endothelial growth factor using changes in conc

241 2.3 +/- 0.6 intravitreal injections of anti-vascular endothelial growth factor without significant i

242 dothelial cells (BECs) secreted higher VEGF (vascular endothelial growth factor) and lower TSP-1 (thr

243 Although VEGF (vascular endothelial growth factor) improves lung struct

244 lar trauma receiving intravitreal anti-VEGF (vascular endothelial growth factor) injections.

245 Although anti-VEGF (vascular endothelial growth factor) therapy offers short

246 ytokines examined (n = 27) with 1 exception (vascular endothelial growth factor) were overexpressed w

247 ctor, interleukin 1 receptor antagonist, and vascular endothelial growth factor) without significant

248 n blot measurements of HIF-1a, HIF-2a, VEGF (vascular endothelial growth factor), and eNOS (endotheli

249 expression of pro-angiogenic factors VEGFA (vascular endothelial growth factor), FGF2 (fibroblast gr

250 aturally high endogenous expression of VEGF (vascular endothelial growth factor).

251 eta1, and the angiogenic growth factor VEGF (vascular endothelial growth factor).

252 Twenty-four patients were treated with anti-vascular endothelial growth factor, and 21 patients were

253 s, which include fibroblast growth factor-2, vascular endothelial growth factor, and apolipoprotein-D

254 r RNAs encoding genes involved in metabolic, vascular endothelial growth factor, and extracellular si

255 factors, platelet-derived growth factor-AA, vascular endothelial growth factor, and others) were fou

256 actors such as interferon-gamma (IFN-gamma), vascular endothelial growth factor, and soluble vascular

257 h slow releasing insulin growth factor 1 and vascular endothelial growth factor, followed by intramyo

258 p epidermal growth factor homology domain 2, vascular endothelial growth factor, soluble fms-like tyr

259 a humanized monoclonal antibody that targets vascular endothelial growth factor, to platinum-based ch

260 higher angiopoietin-2/angiopoietin-1 ratio, vascular endothelial growth factor, vascular cell adhesi

261 p epidermal growth factor homology domain 2, vascular endothelial growth factor, von Willebrand facto

262 ukin-8, transforming growth factor beta, and vascular endothelial growth factor-1 compared to nonneop

263 Vascular endothelial growth factor-A (VEGF) is the angio

264 Vascular endothelial growth factor-A (VEGF) plays a crit

265 Here we show that vascular endothelial growth factor-A (VEGF-A) and platel

266 LAN was associated with reduced hippocampal vascular endothelial growth factor-A (VEGF-A) in both ma

267 xes, specifically whether macrophage-derived vascular endothelial growth factor-A (Vegf-A) is crucial

268 in vitro VWF binds to several GFs, including vascular endothelial growth factor-A (VEGF-A) isoforms a

269 otein in HNSCC cells of invaded lymph nodes, vascular endothelial growth factor-A (VEGF-A), vascular

270 ecific antibody targeting angiopoietin-2 and vascular endothelial growth factor-A (VEGF-A), with rani

271 underlying cause of this regulation, via the vascular endothelial growth factor-A (VEGF-A)/VEGF recep

272 ndc3b in cardiac endothelial cells increases vascular endothelial growth factor-A expression and enha

273 In addition, vascular endothelial growth factor-A levels were negativ

274 Transforming growth factor-beta(1) and vascular endothelial growth factor-A secretion was measu

275 , histology, and imunnohistochemistry (Ki67, vascular endothelial growth factor-A vascular endothelia

276 it functions largely independent of VEGF-A (vascular endothelial growth factor-A).

277 ence for transforming growth factor-beta(1), vascular endothelial growth factor-A/C, and cAMP/ERK exp

278 pretransfected with adeno-associated virus 1-vascular endothelial growth factor-A165 under control of

279 Vascular endothelial growth factor-C (VEGF-C) acts prima

280 y reported a feedback loop between PROX1 and vascular endothelial growth factor-C (VEGF-C) signaling.

281 scular endothelial growth factor-A (VEGF-A), vascular endothelial growth factor-C (VEGF-C) were posit

282 study, we identified a critical function for vascular endothelial growth factor-C (VEGF-C), that of m

283 biomarkers prostate specific antigen (PSA), vascular endothelial growth factor-D (VEGF-D), ETS-relat

284 Vascular endothelial growth factor-inhibitor (VEGF-I) th

285 Modulation of vascular endothelial growth factor-mediated immune suppr

286 nitor cells (sprocs) from the bone marrow by vascular endothelial growth factor-stromal cell-derived

287 Other than vascular endothelial growth factor-vascular endothelial

288 on of tumor insulin-like growth factor-I and vascular endothelial growth factor.

289 eaved high-molecular-weight kininogen (cHK), vascular endothelial growth factors (VEGFs), angiopoieti

290 The mechanism of maintaining vascular endothelial identity and integrity is largely u

291 Following vascular endothelial injury, Wnt activation in MVPC was

292 o neurons, fibroblasts, oligodendrocytes and vascular endothelial-like cells that have molecular and

293 is compromised in diabetes, leading to poor vascular endothelial repair, which contributes to impair

294 The role of vascular endothelial signals in tailoring the phenotype

295 prouting vascular front while S1PR-dependent vascular endothelial (VE)-cadherin assembly suppresses J

296 a the Rho-dependent myosin light chain 2 and vascular endothelial (VE)-cadherin axis.

297 Vascular endothelial (VE)-cadherin forms homotypic adher

298 Strikingly, vascular endothelial (VE)-cadherin phosphorylation at th

299 ntified the endothelial transcription factor vascular endothelial zinc finger 1 (VEZF1) as a direct t

300 Vascular endothelial zinc finger 1 (VEZF1) plays importa